Senior Scientist, Degrader Antibody Conjugate Cellular Pharmacology
- Salary
- ₹10–20 LPA
- Location
- Brisbane
- Experience
- Senior
About company
Senior Scientist - Degrader Antibody Conjugate Cellular Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Position: We are seeking an accomplished scientific leader who will define and drive our in vitro screening and pharmacological characterization capability for Degrader Antibody Conjugates (DACs). Our DAC platform pairs antibody-based targeting with our degrader expertise to direct protein degradation to specific cell types, and this scientist will own the in vitro strategy defining how candidate molecules move through the screening cascade — from primary screening through mechanistic pharmacological characterization of drug candidates. This is a hands-on leadership role for someone who has built deep expertise in the ADC and/or DAC field and wants to apply that experience in designing and running in vitro pharmacology studies into a highly collaborative discovery organization, while operating with a high degree of scientific independence. The scientist will independently design, execute, and analyze cellular assays that characterize DAC activity, and will partner closely with discovery biology, conjugation chemistry, analytical biochemistry, DMPK, and automation to advance candidates from early screening through development candidate selection. Success depends as much on scientific visio